Sarepta Therapeutics in its fourth-quarter and full-year 2023 earnings report on Wednesday touted the strong market demand for its Duchenne muscular dystrophy gene therapy Elevidys (delandistrogene moxeparvovec-rokl), which brought in just over $200 million since its launch in mid-2023.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,